Figure 4.

NTD (N) between AF1 and ID acts as a spacer for hormone agonist activity. A, Schematic illustration of PR-B constructs including WT-PR-B, internal deletions (Δ323-475) (Δ475-534), and AF1 duplication. B, COS-1 cells were transfected with PRE₂-TATA-Luc (200 ng) together with phPR-B expressing wild-type or PR-B constructs depicted in panel A (0.5–25 ng). Cells were treated with vehicle or 10 nm R5020 for the final 24 h of transfection. C, COS-1 cells were transfected with PRE₂-TATA-Luc (200 ng) together with single concentrations (1.5) of WT-PR-B and PR constructs in the presence or absence of pCR3.1-JDP-2 (100 ng). Cells were treated for the final 24 h with vehicle, 10 nm R5020, or RU486, as indicated. Fold luciferase induction by ligand and fold enhancement by JDP-2 was calculated as in Fig. 1. Values are averages ± sem of at least three independent experiments. WT, Wild type.